Expansion Opportunities QPS is actively expanding its physical footprint with new and expanded facilities in Newark, New Jersey and Springfield, Massachusetts, signaling capacity and capability growth that could benefit clients seeking larger-scale CRO support and regional access in the US.

Clinical Trials Focus With strong capabilities in neuropharmacology, DMPK, toxicology, bioanalysis, translational medicine, and clinical development, QPS presents a compelling partner for sponsors needing end-to-end discovery through late-stage clinical services, especially for CNS and translational programs.

Technology Leverage QPS has invested in LC-MS expansion and leverages cloud and analytics tools (Azure, Office 365, Cloudflare, SQL) and automation-friendly platforms, offering opportunities to position QPS as a tech-forward CRO for optimized data quality, faster timelines, and integrated analytics.

Strategic Partnerships Recent collaborations, including Ryght AI and continued leadership in cell therapy facilities, indicate a growth-oriented ecosystem where joint ventures could unlock enhanced trial optimization, bioanalytics, and adaptive study designs for sponsors seeking innovative approaches.

Talent and Capacity A headcount growth initiative in Delaware Technology Park and award-winning quality posture suggest QPS can scale to accommodate larger programs, multi-region studies, and expanded patient population-focused research, presenting a compelling case for outsourcing at scale.